Stellate cells and their progenitor precursors in pancreas cancer progression
胰腺癌进展中的星状细胞及其祖细胞前体
基本信息
- 批准号:8904631
- 负责人:
- 金额:$ 30.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-05 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AMD3100AntibodiesAutomobile DrivingBehaviorBiochemicalBiological AssayBone MarrowBone Marrow TransplantationCXCL12 geneCXCR4 ReceptorsCXCR4 geneCancer EtiologyCarcinomaCellsCessation of lifeChemicalsClinicalCoculture TechniquesConditioned Culture MediaCountryDataDepositionDesmoplasticDiseaseDisease ProgressionDisease ResistanceEpithelial CellsEpitheliumExtracellular MatrixGenerationsGeneticGenetically Engineered MouseGrowth FactorHealthHematopoieticHistopathologyHome environmentHomingHumanHuman Cell LineImmuneIn VitroIncidenceIndigenousInfiltrationInjuryInvestigationLesionLifeMaintenanceMalignant Epithelial CellMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMesenchymalMesenchymal Stem CellsMicroscopicModelingMolecularMouse Cell LineMusMyofibroblastNeoplasm MetastasisPancreasPancreatic Ductal AdenocarcinomaPancreatic Intraepithelial NeoplasiaPancreatic carcinomaPancreatitisParacrine CommunicationPatientsPharmaceutical PreparationsPlayPopulationProcessProteinsProteomeRoleSignal TransductionSmall Interfering RNASolid NeoplasmSourceStagingStem cellsStromal Cell-Derived Factor 1Stromal CellsSurvival RateSyndromeSystemTechnologyTestingTherapy trialTissuesTransgenic MiceWorkXenograft Modelcancer imagingcell behaviorcell growthcell motilitychemotherapeutic agentcombatcytokinehuman diseaseimprovedin vivoinhibitor/antagonistkillingsmortalitymouse modelnew therapeutic targetnovelnovel therapeuticspancreatic neoplasmparacrinepre-clinicalprogenitorprogramsresearch studyresponsesmall hairpin RNAstellate celltargeted treatmenttherapy resistanttumortumor progression
项目摘要
DESCRIPTION (provided by applicant): Pancreatic cancer is an extremely lethal disease with the lowest 1-year and 5-year survival rates of any cancer. This is due, in part, to the extremely metastatic behavior of pancreas carcinoma cells, which are also highly resistant to therapy. Importantly, we now know that a strong, but nevertheless unique, stromal response is present in pancreatic ductal adenocarcinoma (PDA). This is highly relevant as it is now recognized that, in many solid tumors, the local microenvironment and the stromal compartment significantly influences disease progression. In conventional pancreatic ductal adenocarcinoma, and its most common precursor PanIN lesions, disease progression is associated with a robust fibrotic response in the stroma, or desmoplastic reaction, that is largely regulated by pancreatic stellate cells. Even at the early stages of preinvasive disease activation of pancreatic stellate cells and extracellular matrix deposition is robust. Through disease progression this desmoplastic reaction continues and often intensifies, offering critical support to carcinoma cells as they progress to fully metastatic disease while also providing drug-free sanctuaries that limit access of chemotherapeutic agents. However, to date, the molecular and physical mechanisms by which PSCs regulate epithelial carcinoma cell behavior in vivo are not well understood. Likewise, the molecular mechanisms by which PSCs are activated as well as the source of activated PSCs in the tumor remains to be fully elucidated. In culture, stellate cells are known to
secrete factors that can promote cell behaviors associated with tumor progression, suggesting a paracrine signaling role for stellate cells in indigenous disease in vivo. Therefore, here, using murine models of pancreas cancer that faithfully mimics the human disease and human cell line grafted tumors, we propose specific experiments to explicitly investigate the source of activated pancreatic stellate cells in pancreas cancer, dissect the role of stromal stellate cells population in preinvasive, invasive and metastatic disease, and specifically target a key stellate cell-derive cytokine that promotes carcinoma cell growth and motility and contributes to the generation and maintenance of the desmoplastic reaction in PDA. We hypothesize that bone marrow-derived progenitor cells are a source of activated pancreatic stellate cells that are co-opted, along with endogenous populations of stellate cells, in early preinvasive lesions to help drive conversion to PDA and ultimately establish successful metastases. Furthermore, we hypothesize that chemical signal draws bone marrow-derived progenitor cells to PDA but that physical features of the stroma also influence their infiltration and subsequent differentiation and that specific strom targeting therapy can disrupt these interactions and the tumor supporting influence of stellate cells in PDA.
描述(由申请人提供):胰腺癌是一种极其致命的疾病,在所有癌症中1年和5年生存率最低。这部分是由于胰腺癌细胞的极端转移行为,其也对治疗具有高度抗性。重要的是,我们现在知道胰腺导管腺癌(PDA)存在强烈但独特的间质反应。这是高度相关的,因为现在认识到,在许多实体瘤中,局部微环境和间质区室显著影响疾病进展。在常规胰腺导管腺癌及其最常见的前体PanIN病变中,疾病进展与间质中强烈的纤维化反应或促结缔组织增生反应相关,这在很大程度上受到胰腺星状细胞的调节。即使在侵袭前疾病的早期阶段,胰腺星状细胞的活化和细胞外基质沉积也是稳健的。通过疾病进展,这种促结缔组织增生反应持续并经常加剧,为癌细胞提供关键支持,因为它们进展到完全转移性疾病,同时还提供了限制化疗药物进入的无药避难所。然而,迄今为止,PSC调节上皮癌细胞体内行为的分子和物理机制还不清楚。同样,PSC被激活的分子机制以及肿瘤中激活的PSC的来源仍有待充分阐明。在培养中,已知星状细胞
分泌因子,可以促进与肿瘤进展相关的细胞行为,表明星状细胞在体内固有疾病中的旁分泌信号作用。因此,在这里,使用忠实地模拟人类疾病和人类细胞系移植肿瘤的胰腺癌小鼠模型,我们提出了具体的实验来明确研究胰腺癌中活化的胰腺星状细胞的来源,剖析基质星状细胞群体在浸润前、浸润性和转移性疾病中的作用,并且特异性靶向促进癌细胞生长和运动并有助于PDA中促结缔组织增生反应的产生和维持的关键星状细胞衍生的细胞因子。我们假设骨髓来源的祖细胞是活化的胰腺星状细胞的来源,这些细胞与内源性星状细胞群体一起沿着在早期浸润前病变中被选择,以帮助驱动转化为PDA并最终建立成功的转移。此外,我们假设化学信号将骨髓源性祖细胞吸引到PDA,但基质的物理特征也影响其浸润和随后的分化,并且特定的strom靶向治疗可以破坏这些相互作用和PDA中星状细胞的肿瘤支持影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paolo Provenzano其他文献
Paolo Provenzano的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paolo Provenzano', 18)}}的其他基金
A platform to functionally sort and analyze tumor cells within combinatorial metastatic micorenvironments
在组合转移微环境中对肿瘤细胞进行功能分类和分析的平台
- 批准号:
10632016 - 财政年份:2020
- 资助金额:
$ 30.9万 - 项目类别:
A platform to functionally sort and analyze tumor cells within combinatorial metastatic micorenvironments
在组合转移微环境中对肿瘤细胞进行功能分类和分析的平台
- 批准号:
10161754 - 财政年份:2020
- 资助金额:
$ 30.9万 - 项目类别:
A platform to functionally sort and analyze tumor cells within combinatorial metastatic micorenvironments
在组合转移微环境中对肿瘤细胞进行功能分类和分析的平台
- 批准号:
10414891 - 财政年份:2020
- 资助金额:
$ 30.9万 - 项目类别:
Stellate cells and their progenitor precursors in pancreas cancer progression
胰腺癌进展中的星状细胞及其祖细胞前体
- 批准号:
8759844 - 财政年份:2014
- 资助金额:
$ 30.9万 - 项目类别:
Stellate cells and their progenitor precursors in pancreas cancer progression
胰腺癌进展中的星状细胞及其祖细胞前体
- 批准号:
9307750 - 财政年份:2014
- 资助金额:
$ 30.9万 - 项目类别:
Stellate cells and their progenitor precursors in pancreas cancer progression
胰腺癌进展中的星状细胞及其祖细胞前体
- 批准号:
9243147 - 财政年份:2014
- 资助金额:
$ 30.9万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 30.9万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 30.9万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 30.9万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 30.9万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 30.9万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 30.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 30.9万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 30.9万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 30.9万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 30.9万 - 项目类别: